When a patient with pauci-immune crescentic glomerulonephritis starts cyclophosphamide and high-dose glucocorticoids, a TMP-SMX order may be appropriate—but not for every reason written beside it. The key distinction is that Pneumocystis jirovecii pneumonia (PJP) prophylaxis is supported during potent induction therapy; routine TMP-SMX as a vasculitis-remission strategy is a different claim and should not be assumed.
Consider a 24-year-old with dark urine and edema whose creatinine rises from 248 to 398 µmol/L over 48 hours. Biopsy shows ANCA-associated pauci-immune crescentic glomerulonephritis, and the team plans cyclophosphamide with glucocorticoids. Before adding prophylaxis, clarify the purpose, expected duration, allergy history, current potassium, blood count, medication list, and kidney-function trend. The creatinine is changing rapidly, so a single calculated estimate may not represent stable kidney function for dosing.
Keep the two indications separate
For patients receiving cyclophosphamide or rituximab for ANCA-associated vasculitis, specialty guidance supports low-dose TMP-SMX—or an alternative—for PJP prevention. Some guidance also considers prophylaxis for selected patients receiving prolonged high-dose glucocorticoids. That is infection prevention during immunosuppression, not treatment of the vasculitis itself.
| Clinical question | What the evidence supports | The leap to avoid |
|---|---|---|
| Why prescribe TMP-SMX during induction? | To reduce PJP risk during high-risk immunosuppression; use a regimen appropriate to the patient and local protocol. | Calling it treatment for active glomerular inflammation. |
| Does it routinely prevent GPA relapse? | Current guidance does not support adding it routinely as remission-maintenance therapy. It may be considered in selected sinonasal disease. | Assuming nasal Staphylococcus aureus carriage makes systemic TMP-SMX a universal relapse-prevention prescription. |
| What if creatinine rises after starting it? | Trimethoprim can inhibit tubular creatinine secretion and cause a reversible rise without a true fall in GFR. | Dismissing every rise as harmless when active GN or drug-related kidney injury remains possible. |
Some studies have linked chronic nasal S. aureus carriage with relapse in granulomatosis with polyangiitis (GPA). An association does not establish that routine systemic TMP-SMX at a PJP-prophylaxis dose prevents relapse. Earlier studies of different, treatment-level regimens also should not be taken as proof that a lower prophylactic schedule can replace established remission-maintenance therapy. If the patient has active or recurrent sinonasal disease, that is a separate clinical problem to discuss with the vasculitis team; it does not change the primary purpose of this prophylaxis order.
Active AKI changes how you use the drug
TMP-SMX is not a “set and forget” prescription in someone with rapidly changing kidney function. Review renal dosing with pharmacy or nephrology, and reassess as kidney function evolves rather than treating a non-steady-state creatinine-based estimate as precise. Check the blood count and potassium, and arrange follow-up kidney-function and electrolyte testing after initiation or dose changes.
Trimethoprim acts in the distal nephron in a way that can reduce potassium excretion. Hyperkalemia is therefore a particularly important potential complication when GFR is already low; review other contributors, including potassium supplements and drugs that raise potassium. A new potassium rise should not automatically be attributed to the glomerulonephritis.
Creatinine needs the same careful reading. A small increase after starting trimethoprim may reflect reduced tubular secretion rather than worsening filtration, but this patient already has active kidney injury. Check the timing and magnitude of the change alongside urine output, potassium, urea, symptoms, medication exposures, and the broader renal trajectory. TMP-SMX can also cause true kidney injury, so “pseudo-rise” is a possibility to evaluate—not a conclusion to assume.
Choose the prophylaxis plan, then make it reviewable
For ANCA-associated vasculitis, guidance advises PJP prophylaxis through the cyclophosphamide course or for about six months after rituximab induction. Longer use may be appropriate in selected patients with repeated rituximab, structural lung disease, or ongoing immunosuppression or glucocorticoids. The stop date should be linked to the regimen and changing risk, not left as an indefinite default.
If TMP-SMX is unsuitable, alternatives include atovaquone, dapsone, or inhaled pentamidine, selected for the patient’s circumstances. Check glucose-6-phosphate dehydrogenase status before dapsone. A serious sulfonamide reaction, troublesome hyperkalemia, or a renal adverse effect should prompt a deliberate alternative plan—not simply abandonment of PJP prevention.
Common traps on rounds
- Conflating prevention with disease control: PJP prophylaxis does not induce or maintain vasculitis remission.
- Turning colonization into causation: A reported association between nasal carriage and relapse does not establish a routine TMP-SMX indication for every patient.
- Calling every creatinine rise “pseudo”: Trimethoprim can alter creatinine secretion, but true GN progression or drug-related kidney injury still needs assessment.
- Forgetting the monitoring plan: In active AKI, renal dosing, potassium, and blood counts deserve explicit follow-up.
Practical takeaways
- In ANCA vasculitis treated with cyclophosphamide or rituximab, consider TMP-SMX or an alternative primarily for PJP prophylaxis.
- Do not use routine low-dose TMP-SMX as a substitute for evidence-based vasculitis remission-maintenance therapy.
- In active AKI, reassess renal dosing and monitor potassium, creatinine, and blood counts.
- Treat a creatinine rise after TMP-SMX as a finding to interpret—not automatically as GN progression or a harmless drug effect.
